natgillin/translations-raw huggingface dataset:
Docetaxel blocks the ability of cells to destroy the internal ‘ skeleton ’ that allows them to divide and multiply.
Docetaksel blokira sposobnost celic za uničevanje notranjega „ skeleta “, kar jim omogoča deljenje in razmnoževanje.
Docetaxel Winthrop has been studied in a total of around 3,000 breast cancer patients, around 1,900 lung cancer patients, around 1,000 prostate cancer patients, 445 stomach cancer patients and 897 in head and neck cancer patients.
Zdravilo Docetaxel Winthrop so preučevali pri približno 3. 000 bolnicah z rakom dojke, 1. 900 bolnikih s pljučnim rakom, 1000 bolnikih z rakom prostate, 445 bolnikih z želodčnim rakom in 897 bolnikih z rakom glave in vratu.
In most of these studies, Docetaxel Winthrop was combined with other anticancer treatments and compared with combinations of different treatments or the same treatment without Docetaxel Winthrop.
Pri večini teh študij so zdravilo Docetaxel Winthrop kombinirali z drugimi oblikami zdravljenja proti raku in ga primerjali s kombinacijami različnih oblik zdravljenja ali enakim zdravljenjem brez zdravila Docetaxel Winthrop.
The main measure of effectiveness were the response rates (percentage of patients whose cancer responded to treatment), the time taken for the disease to progress and the increase in survival time.
Glavna merila učinkovitosti zdravila so bila stopnja odziva (odstotek bolnikov, pri katerih se je rak odzval na zdravljenje), čas do napredovanja bolezni in podaljšanje časa preživetja.
What benefit has Docetaxel Winthrop shown during the studies?
Kakšne koristi je zdravilo Docetaxel Winthrop izkazalo med raziskavami?
The addition of Docetaxel Winthrop to other anticancer treatments produced significant increases in response rates, disease progression or survival, in all five types of cancer (breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma and head and neck cancer).
Dodajanje zdravila Docetaxel Winthrop drugim oblikam zdravljenja proti raku je pokazalo pomembno povečanje stopnje odziva, napredovanja bolezni ali preživetja pri vseh petih vrstah raka (raku dojke, nedrobnoceličnem pljučnem raku, raku prostate, želodčnem adenokarcinomu in raku glave in vratu).
Used on its own in breast cancer, Docetaxel Winthrop was at least as effective as, and sometimes more effective than the comparator medicines.
Kadar se je uporabljalo kot monoterapija pri raku dojke, je bilo zdravilo Docetaxel Winthrop vsaj tako učinkovito kot primerjalna zdravila, včasih pa tudi bolj učinkovito kot primerjalna zdravila.
It was more effective than best supportive care therapy in lung cancer.
Proti pljučnemu raku je bilo učinkovitejše kot zdravljenje z najboljšo podporno nego.
The most common side effects in patients receiving Docetaxel Winthrop (seen in more than 1 patient in 10) are neutropenia (reduced white blood cell counts), anaemia (reduced red blood cell counts), thrombocytopenia (low blood platelet counts), febrile neutropenia (neutropenia with fever), peripheral sensory neuropathy (damage to the nerves causing numbness, tingling and pain in the hands and feet), peripheral motor neuropathy (damage to the nerves causing difficulty co-ordinating movements), dysgeusia (taste disturbances), dyspnoea (shortness of breath), stomatitis (inflammation of the lining of the mouth), diarrhoea, nausea (feeling sick), vomiting, alopecia (hair loss), skin reactions, nail disorders, myalgia (muscle pain), anorexia (loss of appetite), infections, fluid retention, asthenia (weakness), pain and hypersensitivity (allergic reactions).
Najpogostejši neželeni učinki pri bolnikih, ki prejemajo zdravilo Docetaxel Winthrop (opaženi pri več kot 1 bolniku od 10), so nevtropenija (zmanjšano število belih krvnih celic), anemija (zmanjšano število rdečih krvnih celic), trombocitopenija (nizko število trombocitov), febrilna nevtropenija (nevtropenija s povišano telesno temperaturo), periferna senzorična nevropatija (poškodbe živcev, katerih posledica je otrplost, mravljinčenje in bolečine v rokah in nogah), periferna motorična nevropatija (poškodbe živcev, ki otežujejo koordinacijo gibov), dizgevzija (motnje okušanja), dispneja (zasoplost), stomatisis (vnetje ustne sluznice), driska, navzea (občutek slabosti), bruhanje, alopecija (izpadanje las), kožne reakcije, prizadetost nohtov, mialgija (bolečine v mišicah), anoreksija (izguba apetita), okužbe, zastajanje tekočine, astenija (šibkost), bolečine in preobčutljivost (alergične reakcije).
For the full list of all side effects reported with Docetaxel Winthrop, see the Package Leaflet.
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Docetaxel Winthrop, glejte Navodilo za uporabo.
Docetaxel Winthrop should not be used in people who may be hypersensitive (allergic) to docetaxel or any of the other ingredients.
Zdravila Docetaxel Winthrop se ne sme uporabljati pri osebah, ki utegnejo biti preobčutljive za (alergične na) docetaksel ali katero koli drugo sestavino zdravila.
Docetaxel Winthrop should not be used in patients who have a neutrophil count of less than 1,500 cells/ mm3, in pregnant or breast-feeding women, or in patients who have severe liver disease.
Zdravila Docetaxel Winthrop se ne sme uporabljati pri bolnikih s številom nevtrofilcev, manjšim od 1. 500 celic/ mm3, pri nosečnicah ali ženskah, ki dojijo, ali pri bolnikih s hudo boleznijo jeter.
The Committee for Medicinal Products for Human Use (CHMP) decided that Docetaxel Winthrop’ s benefits are greater than its risks for the treatment of breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma and squamous cell head and neck cancer.
Odbor za zdravila za uporabo v humani medicini (CHMP) meni, da so za zdravljenje raka dojke, nedrobnoceličnega pljučnega raka, raka prostate, želodčnega adenokarcinoma in raka skvamoznih celic v glavi in vratu koristi zdravila Docetaxel Winthrop večje od z njim povezanih tveganj.
The Committee recommended that Docetaxel Winthrop be given marketing authorisation.
Odbor je zato priporočil, da se za zdravilo Docetaxel Winthrop odobri dovoljenje za promet.
The European Commission granted a marketing authorisation valid throughout the European Union for Docetaxel Winthrop to Aventis Pharma S. A. on 20 April 2007.
Evropska komisija je dovoljenje za promet z zdravilom Docetaxel Winthrop, veljavno po vsej Evropski uniji, odobrila družbi Aventis Pharma S. A. dne 20 aprila 2007.
The full EPAR for Docetaxel Winthrop is available here.
Celotno Evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Docetaxel Winthrop je na voljo tukaj.
EU/ 1/ 07/ 384/ 001
Številka EU EU/ 1/ 07/ 384/ 001
Docetaxel Winthrop
Izmišljeno ime Docetaxel Winthrop
20 mg
jakost 20 mg
Concentrate and solvent for solution for infusion
farmacevtska oblika koncentrat in vehikel za raztopino za infundiranje
Intravenous use
pot uporabe intravenska uporaba
Concentrate: vial (glass); Solvent: vial (glass)
ovojnina koncentrat: viala (steklo) vehikel: viala (steklo)
Concentrate:
vsebina koncentrat:
0.5 ml; Solvent:
0, 5ml vehikel:
1 vial + 1 vial
velikost pakiranja 1 viala + 1 viala
Concentrate: vial (glass); Solvent: vial (glass)
koncentrat: viala (steklo) vehikel: viala (steklo)
Concentrate:
koncentrat:
2 ml; Solvent:
2 ml vehikel:
Docetaxel Winthrop 20 mg concentrate and solvent for solution for infusion
Docetaxel Winthrop 20 mg koncentrat in vehikel za raztopino za infundiranje
Each single-dose vial of Docetaxel Winthrop 20 mg concentrate contains docetaxel which is a trihydrate corresponding to 20 mg of docetaxel (anhydrous).
Vsaka viala z enim odmerkom zdravila Docetaxel Winthrop 20 mg koncentrat vsebuje docetaksel v obliki trihidrata, ki ustreza 20 mg brezvodnega docetaksela.
The viscous solution contains 40 mg/ ml docetaxel (anhydrous).
Viskozna raztopina vsebuje 40 mg/ ml brezvodnega docetaksela.
Each single-dose vial of solvent contains 13% (w/ w) ethanol 95% in water for injection.
Vsaka viala z enim odmerkom vehikla vsebuje 13% (m/ m) 95% etanola v vodi za injekcije.
The concentrate is a clear viscous, yellow to brown-yellow solution.
Koncentrat je bistra, viskozna, rumena do rjavo- rumena raztopina.
Docetaxel Winthrop in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node- positive breast cancer.
Docetaxel Winthrop je v kombinaciji z doksorubicinom in ciklofosfamidom indiciran za adjuvantno zdravljenje bolnic z operabilnim rakom dojke s pozitivnimi bezgavkami.
Docetaxel Winthrop in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.
Docetaxel Winthrop v kombinaciji z doksorubicinom je indiciran za zdravljenje bolnic z lokalno napredovalim ali metastatskim rakom dojke, ki zaradi te bolezni še niso prejemale citotoksične terapije.
Docetaxel Winthrop monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy.
Docetaxel Winthrop v monoterapiji je indiciran za zdravljenje bolnic z lokalno napredovalim ali metastatskim rakom dojke, pri katerih predhodna citotoksična terapija ni bila uspešna.
Docetaxel Winthrop in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumors overexpress HER2 and who previously have not received chemotherapy for metastatic disease.
Docetaxel Winthrop je indiciran v kombinaciji s trastuzumabom za zdravljenje bolnic z metastatskim rakom dojke, katerih tumorji imajo čezmerno izražen HER2 in ki predhodno niso bile zdravljene s kemoterapijo za metastatsko bolezen.
Docetaxel Winthrop in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy.
Docetaxel Winthrop v kombinaciji s kapecitabinom je indiciran za zdravljenje bolnic z lokalno napredovalim ali metastatskim rakom dojke po neuspehu citotoksične kemoterapije.
Docetaxel Winthrop is indicated for the treatment of patients with locally advanced or metastatic non- small cell lung cancer after failure of prior chemotherapy.
Docetaxel Winthrop je indiciran za zdravljenje bolnikov z lokalno napredovalim ali metastatskim nedrobnoceličnim pljučnim rakom, pri katerih predhodna kemoterapija ni bila uspešna.
Docetaxel Winthrop in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer, in patients who have not previously received chemotherapy for this condition.
Docetaxel Winthrop v kombinaciji s cisplatinom je indiciran za zdravljenje neresektabilnega, lokalno napredovalega ali metastatskega nedrobnoceličnega pljučnega raka pri bolnikih, ki zaradi te bolezni še niso dobivali kemoterapije.
2 Prostate cancer
2 Rak prostate
Docetaxel Winthrop in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer.
Docetaxel Winthrop je v kombinaciji s prednizonom ali prednizolonom indiciran za zdravljenje bolnikov z metastatskim hormonsko neodzivnim rakom prostate.
Docetaxel Winthrop in combination with cisplatin and 5-fluorouracil is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease.
Docetaxel Winthrop je v kombinaciji s cisplatinom in 5- fluorouracilom indiciran za zdravljenje bolnikov z metastatskim adenokarcinomom želodca, vključno z adenokarcinomom na gastroezofagealnem prehodu, ki predhodno še niso bili zdravljeni s kemoterapijo za metastatsko bolezen.
Docetaxel Winthrop in combination with cisplatin and 5-fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.
Docetaxel Winthrop je v kombinaciji s cisplatinom in 5- fluorouracilom indiciran za indukcijsko zdravljenje bolnikov z lokalno napredovalim skvamoznoceličnim karcinomom glave in vratu.
The use of docetaxel should be confined to units specialised in the administration of cytotoxic chemotherapy and it should only be administered under the supervision of a physician qualified in the use of anticancer chemotherapy (see section 6.6).
Docetaksel se sme uporabljati le v enotah, specializiranih za citotoksično kemoterapijo in samo pod nadzorom zdravnika, izkušenega na področju onkološke kemoterapije (glejte poglavje 6. 6).
For breast, non-small cell lung, gastric, and head and neck cancers, premedication consisting of an oral corticosteroid, such as dexamethasone 16 mg per day (e. g.
Pri zdravljenju raka dojke, nedrobnoceličnega pljučnega raka, raka želodca ter raka glave in vratu lahko kot premedikacijo dajemo peroralne kortikosteroide, kot je deksametazon 16 mg na dan (npr.
8 mg BID) for 3 days starting 1 day prior to docetaxel administration, unless contraindicated, can be used (see section 4.4).
8 mg dvakrat dnevno) v trajanju treh dni, in sicer 1 dan pred aplikacijo docetaksela, razen v primeru kontraindikacij (prosimo, glejte poglavje 4. 4).
Prophylactic G-CSF may be used to mitigate the risk of hematological toxicities.
Profilaktični G- CSF (granulocyte– colony stimulating factor; granulocitne kolonije stimulirajoči faktor) se lahko uporabi za ublažitev tveganja hematološke toksičnosti.
For prostate cancer, given the concurrent use of prednisone or prednisolone the recommended premedication regimen is oral dexamethasone 8 mg, 12 hours, 3 hours and 1 hour before the docetaxel infusion (see section 4.4).
Pri zdravljenju raka prostate, v primeru sočasne uporabe prednizona ali prednizolona, je priporočena premedikacija peroralni deksametazon 8 mg, 12 ur, 3 ure in 1 uro pred infuzijo docetaksela (prosimo, glejte poglavje 4. 4).
Breast cancer In the adjuvant treatment of operable node-positive breast cancer, the recommended dose of docetaxel is 75 mg/ m2 administered 1-hour after doxorubicin 50 mg/ m2 and cyclophosphamide 500 mg/ m2 every 3 weeks for 6 cycles (see also Dose adjustments during treatment).
Rak dojke Pri dopolnilnem zdravljenju operabilnega raka dojke s pozitivnimi bezgavkami je priporočeni odmerek docetaksela 75 mg/ m2, apliciran eno uro po doksorubicinu 50 mg/ m2 in ciklofosfamidu 500 mg/ m2 vsake tri tedne po 6 ciklusov (glejte tudi Prilagajanje odmerka med zdravljenjem).
For the treatment of patients with locally advanced or metastatic breast cancer, the recommended dose of docetaxel is 100 mg/ m2 in monotherapy.
Za zdravljenje bolnic z lokalno napredovalim ali metastatskim rakom dojke je priporočeni odmerek docetaksela v monoterapiji 100 mg/ m2.
In first-line treatment, docetaxel 75 mg/ m2 is given in combination therapy with doxorubicin (50 mg/ m2).
Kot zdravljenje prvega izbora se docetaksel 75 mg/ m2 daje v kombinaciji z doksorubicinom (50 mg/ m2).
In combination with trastuzumab the recommended dose of docetaxel is 100 mg/ m2 every three weeks, with trastuzumab administered weekly.
Za kombinacijo s trastuzumabom je priporočeni odmerek docetaksela 100 mg/ m2 vsake tri tedne, s tedensko aplikacijo trastuzumaba.
In the pivotal trial the initial docetaxel infusion was started the day following the first dose of trastuzumab.
V raziskavi osrednjega pomena so s prvo infuzijo docetaksela začeli dan po prvem odmerku trastuzumaba.
In combination with capecitabine, the recommended dose of docetaxel is 75 mg/ m2 every three weeks, combined with capecitabine at 1250 mg/ m2 twice daily (within 30 minutes after a meal) for 2 weeks followed by 1-week rest period.
V kombinaciji s kapecitabinom je priporočeni odmerek docetaksela 75 mg/ m2 na tri tedne, kombiniran s kapecitabinom 1. 250 mg/ m2 dvakrat na dan (v 30 minutah po obroku) 2 tedna, čemur sledi 1- tedenski premor.
For treatment
3 Nedrobnocelični pljučni rak Pri bolnikih z nedrobnoceličnim pljučnim rakom, ki še niso bili zdravljeni s kemoterapijo, je priporočena shema odmerjanja docetaksel v odmerku 75 mg/ m2, ki mu takoj sledi cisplatin v odmerku 75 mg/ m2, apliciran 30– 60 minut.
3 after failure of prior platinum-based chemotherapy, the recommended dose is 75 mg/ m² as a single agent.
Za zdravljenje po neuspehu predhodne, na platini osnovane kemoterapije, je priporočeni odmerek 75 mg/ m2 v monoterapiji.
Prostate cancer The recommended dose of docetaxel is 75 mg/ m2.
Rak prostate Priporočeno odmerjanje docetaksela je 75 mg/ m2.
Prednisone or prednisolone 5 mg orally twice daily is administered continuously (see section 5.1).
Prednizon ali prednizolon v odmerku 5 mg dvakrat na dan dajemo nepretrgoma (prosimo, glejte poglavje 5. 1).
Gastric adenocarcinoma The recommended dose of docetaxel is 75 mg/ m2 as a 1 hour infusion, followed by cisplatin 75 mg/ m2, as a 1 to 3 hour infusion (both on day 1 only), followed by 5-fluorouracil 750 mg/ m2 per day given as a 24-hour continuous infusion for 5 days, starting at the end of the cisplatin infusion.
Adenokarcinom želodca Priporočeni odmerek docetaksela je 75 mg/ m2 v 1- urni infuziji, ki mu sledi cisplatin 75 mg/ m2 v 1 - do 3- urni infuziji (oboje samo 1. dan); temu sledi 5- fluorouracil 750 mg/ m2 na dan v 24- urni stalni infuziji 5 dni, z začetkom ob koncu infuzije cisplatina.
Prophylactic G-CSF should be used to mitigate the risk of hematological toxicities (see also Dose adjustments during treatment).
Za zmanjšanje tveganja za hematološke toksične učinke je treba profilaktično uporabiti G- CSF (glejte Prilagajanje odmerjanja med zdravljenjem).
Head and neck cancer Patients must receive premedication with antiemetics and appropriate hydration (prior to and after cisplatin administration).
Rak glave in vratu Bolniki morajo dobiti premedikacijo z antiemetiki in primerno hidracijo (pred in po dajanju cisplatina).
Prophylactic G-CSF may be used to mitigate the risk of hematological toxicities.
Za zmanjšanje tveganja za hematološke toksične učinke se lahko profilaktično uporabi G- CSF.
• Induction chemotherapy followed by radiotherapy (TAX 323) For the induction treatment of inoperable locally advanced squamous cell carcinoma of the head and neck (SCCHN), the recommended dose of docetaxel is 75 mg/ m2 as a 1 hour infusion followed by cisplatin 75 mg/ m2 over 1 hour, on day one, followed by 5-fluorouracil as a continuous infusion at 750 mg/ m2 per day for five days.
• Indukcijska kemoterapija in nato radioterapija (TAX 323) Za indukcijsko zdravljenje inoperabilnega lokalno napredovalega skvamoznoceličnega karcinoma glave in vratu (SCCHN – squamous cell carcinoma of the head and neck), je priporočeni odmerek docetaksela 75 mg/ m2 v obliki enourne infuzije, ki ji sledi cisplatin 75 mg/ m2, infundiran 1 uro dolgo prvega dne, temu pa sledi 5- fluorouracil v obliki neprekinjene infuzije v odmerku 750 mg/ m2 na dan pet dni.
• Induction chemotherapy followed by chemoradiotherapy (TAX 324) For the induction treatment of patients with locally advanced (technically unresectable, low probability of surgical cure, and aiming at organ preservation) squamous cell carcinoma of the head and neck (SCCHN), the recommended dose of docetaxel is 75 mg/ m2 as a 1 hour intravenous infusion on day 1, followed by cisplatin 100 mg/ m2 administered as a 30-minute to 3 hour infusion, followed by 5-fluorouracil 1000 mg/ m2/ day as a continuous infusion from day 1 to day 4.
• Indukcijska kemoterapija in nato kemoradioterapija (TAX 324) Za indukcijsko zdravljenje bolnikov z lokalno napredovalim (neresektabilen, majhna verjetnost kirurške ozdravitve, ohranitev organa) skvamoznoceličnim karcinomom glave in vratu (SCCHN) je priporočen odmerek docetaksela 75 mg/ m2 v obliki enourne intravenske infuzije 1. dan, ki mu sledi cisplatin 100 mg/ m2 v 30- minutni do 3- urni infuziji in nato stalna intravenska infuzija 5- fluorouracila 1000 mg/ m2/ dan od 1. do 4. dneva.
For cisplatin and 5-fluorouracil dose modifications, see the corresponding summary of product characteristics.
Za spremembe odmerkov cisplatina in 5- fluorouracila glejte ustrezen povzetek glavnih značilnosti zdravila.
General Docetaxel should be administered when the neutrophil count is ≥ 1,500 cells/ mm3.
Splošno Docetaksel je treba aplicirati, ko je število nevtrofilcev ≥ 1. 500 celic/ mm3.
In patients who experienced either febrile neutropenia, neutrophil < 500 cells/ mm3 for more than one week, severe or cumulative cutaneous reactions or severe peripheral neuropathy during docetaxel therapy, the dose of docetaxel should be reduced from 100 mg/ m2 to 75 mg/ m2 and/ or from 75 to 60 mg/ m².
Pri bolnikih, ki so med zdravljenjem z docetakselom doživeli febrilno nevtropenijo, zmanjšanje števila nevtrofilcev na < 500 celic/ mm3 za več kot en teden, hude ali kumulativne kožne reakcije ali hudo periferno nevropatijo, je treba odmerek docetaksela zmanjšati s 100 mg/ m2 na 75 mg/ m2 oz. s 75 na 60 mg/ m2.
If the patient continues to experience these reactions at 60 mg/ m², the treatment should be discontinued.
Če bolnik tudi pri odmerku 60 mg/ m2 še doživlja te reakcije, je treba zdravljenje prekiniti.
Adjuvant therapy for breast cancer In the pivotal trial in patients who received adjuvant therapy for breast cancer and who experienced complicated neutropenia (including prolonged neutropenia, febrile neutropenia, or infection), it was recommended to use G-CSF to provide prophylactic coverage (eg, day 4 to 11) in all subsequent cycles.
Adjuvantna terapija raka dojke V raziskavi osrednjega pomena pri bolnicah z rakom dojke, pri katerih se je med dopolnilnim zdravljenjem razvila nevtropenija z zapleti (dalj časa trajajoča nevtropenija, febrilna nevtropenija ali okužba), so priporočali profilaktično uporabo G- CSF (npr. od 4. do 11. dne) v vseh naslednjih ciklih zdravljenja.
Patients who continued to experience this reaction should remain on G-CSF and have their docetaxel dose reduced to 60 mg/ m².
Pri bolnicah, pri katerih ta reakcija traja, je treba z dajanjem G- CSF nadaljevati in jim
4 However, in clinical practice neutropenia could occur earlier.
V klinični praksi pa se lahko nevtropenija pojavi bolj zgodaj.
Thus the use of G-CSF should be considered function of the neutropenic risk of the patient and current recommendations.
Potemtakem moramo uporabo G- CSF obravnavati kot funkcijo tveganja nevtropenije in veljavnih priporočil za zdravljenje.
Patients who experience Grade 3 or 4 stomatitis should have their dose decreased to 60 mg/ m².
Bolnicam, pri katerih se razvije stomatitis 3. ali 4. stopnje, moramo odmerek zmanjšati na 60 mg/ m2.
In combination with cisplatin For patients who are dosed initially at docetaxel 75 mg/ m2 in combination with cisplatin and whose nadir of platelet count during the previous course of therapy is < 25,000 cells/ mm3, or in patients who experience febrile neutropenia, or in patients with serious non-hematologic toxicities, the docetaxel dose in subsequent cycles should be reduced to 65 mg/ m2.
V kombinaciji s cisplatinom Bolnikom, ki uvodoma dobijo docetaksel v odmerku 75 mg/ m2 v kombinaciji s cisplatinom in imajo v predhodnem ciklusu zdravljenja najmanjše število trombocitov < 25. 000 celic/ mm3, bolnikom, ki doživijo febrilno nevtropenijo, in bolnikom z resnimi nehematološkimi toksičnimi učinki je treba odmerek docetaksela v naslednjih ciklusih zmanjšati na 65 mg/ m2.